| Identification | More | [Name]
TRICAPRIN | [CAS]
621-71-6 | [Synonyms]
1,2,3-TRIDECANOYLGLYCEROL
1,2,3-TRIDECANOYL-RAC-GLYCEROL
CAPRIN
GLYCERINTRICAPRATE
GLYCEROL TRICAPRINATE
GLYCEROL TRIDECANOATE
GLYCEROL TRIS(DECANOATE)
GLYCERYL TRIDECANOATE
TRICAPRIN
TRICAPRIN (C10:0)
TRIDECANOIN
TRI-N-CAPRIN
1,2,3-propanetriyltridecanoate
2,3-Bis(decanoyloxy)propyl decanoate
Capric acid triglyceride
capricacidtriglyceride
Decanoicacid,1,2,3-propanetriylester
Decanoin, tri-
Dynasan 110
dynasan110 | [EINECS(EC#)]
210-702-0 | [Molecular Formula]
C33H62O6 | [MDL Number]
MFCD00036239 | [Molecular Weight]
554.84 | [MOL File]
621-71-6.mol |
| Safety Data | Back Directory | [Hazard Codes ]
F,Xn | [Risk Statements ]
R11:Highly Flammable.
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S28:After contact with skin, wash immediately with plenty of ... (to be specified by the manufacturer) . | [RIDADR ]
UN 1282 3/PG 2 | [WGK Germany ]
-
| [RTECS ]
HE0100000
| [HS Code ]
29171900 |
| Hazard Information | Back Directory | [Description]
1,2,3-Tridecanoyl glycerol is a triacylglycerol that contains decanoic acid (Item No. 20838) at the sn-1, sn-2, and sn-3 positions. It has been found in human breast milk.1 1,2,3-Tridecanoyl glycerol has been used as a standard for the quantification of triacylglycerols in fish oils by RP-HPLC.2 Formulations containing 1,2,3-tridecanoyl glycerol have been used in cosmetic products as thickening and skin-conditioning agents.3 | [Uses]
Tricaprin is used to construct solid lipid nanoparticles (SLNs) as delivery system for bromocriptine (B682600, Mesylate salt). It is also used in cationic SLNs to enhance p53 tumor suppressor gene transfer to lung cancer cells. | [Definition]
ChEBI: A triglyceride obtained by formal acylation of the three hydroxy groups of glycerol by capric (decanoic) acid. | [General Description]
This certified reference material (CRM) is produced and certified in accordance with ISO/IEC 17025 and ISO 17034. This CRM is traceable to primary material from an NMI, e.g. NIST or NMIJ.
Certified content by quantitative NMR incl. uncertainty and expiry date are given on the certificate.
Download your certificate at: http://www.sigma-aldrich.com. | [in vivo]
Trisdecanoin (Intravenous injection (i.v.); 1h, 4h) can promote the metabolism of long chain fatty acids (LCFA) in the heart muscle of Atgl KO mice in lipotriglyceride lipase (Atgl) gene knockout (KO) mice. Effect of reducing lipid accumulation in the heart of AtglKO mice and improving left ventricular function of AtglKO mice[2].
Trisdecanoin (1145 mg/kg/day; Oral gavage (p.o.); two weeks) can prevent and inhibit the development of abdominal aortic aneurysms and alleviate the apoptosis and dysfunction of early smooth muscle cells (SMCs) in Male Sprague-Dawley rat models[3].
| Animal Model: | Male Sprague-Dawley rats[3] | | Dosage: | 1145 mg/kg/day | | Administration: | Oral gavage (p.o.) | | Result: | There was no significant difference in the incidence of AAA between the control and ricaprylin groups (30.2% vs 24.0%). In contrast, the incidence of AAA in Trisdecanoin was significantly lower than in the control group (30.2% vs. 3.6%).
The AAA rupture rates in control group and C8-TG group were 31.3% and 33.3%, respectively. There was no aneurysm rupture in Trisdecanoin group.
The mean aortic diameter of Trisdecanoin group was significantly lower than that of control group..
|
| [storage]
Store at -20°C |
|
|